5 news items
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
ARVN
17 Jun 24
statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
ARVN
23 May 24
. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
ARVN
PFE
16 May 24
contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
ARVN
9 May 24
StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
ARVN
NVS
7 May 24
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial
- Prev
- 1
- Next